Status:

COMPLETED

Evaluation of Procalcitonin (PCT) as a Marker of Infection Post Living Donated Liver Transplant

Lead Sponsor:

National Hepatology & Tropical Medicine Research Institute

Conditions:

Liver Transplant Infection

Eligibility:

All Genders

18-70 years

Brief Summary

, the study aimed at assessing the frequency of rising procalcitonin associated with infectious complications in immunosuppressed LDLTRx.

Detailed Description

All patients transferred from operative theatre to ICU will be sedated, intubated \& ventilated. They will receive empiric antimicrobial prophylaxis upon admission \& early immunosuppression according...

Eligibility Criteria

Inclusion

  • including adult patients aged ≥18 years old who are recipients for living donated liver transplantation (LTx) at the Department of Liver Transplant of National Hepatology \& Tropical Medicine Research Institute (NHTMRI), between January 2014 and January 2018 \& with no contraindications for early immunosuppression.

Exclusion

  • Patients will be excluded from the study if they are readmitted or had primary graft nonfunction.

Key Trial Info

Start Date :

March 15 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 10 2019

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT03389360

Start Date

March 15 2018

End Date

February 10 2019

Last Update

March 19 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NHTMRI

Cairo, Egypt

Evaluation of Procalcitonin (PCT) as a Marker of Infection Post Living Donated Liver Transplant | DecenTrialz